Regeneron registers Phase 1b hemodialysis study, Phase 1 Graves' disease trial
Two new clinical trial registry entries cover factor XI/XII antibodies in kidney disease patients and a TSHR-blocking antibody for Graves' disease.
Regeneron Pharmaceuticals logged two new trial registry records during the week, one Phase 1b and one Phase 1.
- A Phase 1b, double-blind, randomized study (NCT07759167) will test three monoclonal antibodies, REGN9933 (amrecibart), REGN7508 (cenvacibart), and REGN9533, in people with end-stage kidney disease on hemodialysis. Participants must have ESKD with regular adherence to hemodialysis three times per week and be receiving heparin anticoagulation with no history of intolerability during each dialysis session.1 The study is recruiting at a single site in Belgium with an estimated enrollment of 36 participants, and the main aim is to see what side effects may happen from taking REGN9933, REGN7508, or REGN9533.1
- A Phase 1, single-ascending dose study (NCT07861152, acronym EMERGE) will test REGN24493, an anti-TSHR monoclonal antibody, in adults with Graves' disease. The study is not yet recruiting, with an estimated enrollment of 45 participants, and the main purpose is to learn about the safety of REGN24493 and what side effects it might cause.2
Fact check notes
- Imprecise
Regeneron Pharmaceuticals logged two new trial registry records during the week, one Phase 1b and one Phase 1.
NCT07759167 was first posted in August 2026, not the same week as NCT07861152 (first posted Oct 6, 2026); only the update date coincides, so framing both as newly 'logged' in the same week is slightly misleading. - Checker's noteThe claim that both trials were 'logged during the week' is imprecise: NCT07759167 was first posted in August 2026, well before NCT07861152's October 2026 first posting; only its last-update date coincides with the newer trial's first posting.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.